Plus Therapeutics Inc (OQ:PSTV)

Business Focus: Biotechnology & Medical Research

Aug 13, 2022 01:06 pm ET
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, yesterday presented positive data from two ongoing clinical...
Jul 28, 2022 07:00 am ET
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing...
Jul 27, 2022 07:00 am ET
Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Norman LaFrance, M.D., Chief Medical...
Jul 21, 2022 04:05 pm ET
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the second quarter...
Jul 13, 2022 07:00 am ET
Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2022...
Jul 12, 2022 07:00 am ET
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it has reached a key milestone on the path to...
Jun 22, 2022 07:30 am ET
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, and Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic...
Jun 16, 2022 07:30 am ET
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the completion of enrollment in the first...
Jun 13, 2022 07:05 am ET
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present positive data on its lead...
May 18, 2022 07:00 am ET
Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive...
Apr 26, 2022 07:00 am ET
Plus Therapeutics to Present at the 2022 Q2 Investor Summit
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive...
Apr 21, 2022 04:05 pm ET
Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the first quarter ended...
Apr 19, 2022 07:00 am ET
Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will discuss new data in an oral...
Apr 14, 2022 07:00 am ET
Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2022...
Apr 08, 2022 04:05 pm ET
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the company will present a poster at the...
Apr 05, 2022 07:00 am ET
Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has expanded its partnership with...
Mar 23, 2022 07:00 am ET
Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive...
Mar 22, 2022 07:00 am ET
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the first patient has been dosed in the...
Mar 03, 2022 07:30 am ET
Plus Therapeutics Announces Upcoming Participation at the 2022 SNMMI Therapeutics Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will sponsor and present an industry...
Feb 24, 2022 04:05 pm ET
Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the fourth quarter and...
Feb 22, 2022 07:00 am ET
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced a partnership with Medidata, a Dassault...
Feb 18, 2022 07:00 am ET
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and...
Feb 07, 2022 07:00 am ET
Plus Therapeutics to Present at BIO CEO & Investor Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and...
Jan 07, 2022 07:00 am ET
Plus Therapeutics to Participate in Upcoming January Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and...
Jan 06, 2022 07:30 am ET
Thinking about buying stock in Freeline Therapeutics, Alterity Therapeutics, Siyata Mobile, Plus Therapeutics, or Nine Energy Service?
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FRLN, ATHE, SYTA, PSTV, and NINE.
Jan 06, 2022 07:00 am ET
Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has entered into an agreement...
Jan 04, 2022 07:30 am ET
Thinking about buying stock in Plus Therapeutics, Neurobo Pharmaceuticals, Flora Growth, Paysign, or Sio Gene Therapies?
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, NRBO, FLGC, PAYS, and SIOX.
Jan 04, 2022 07:00 am ET
Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it has met two significant milestones as it...
Dec 02, 2021 07:30 am ET
Plus Therapeutics to Present at MedInvest Oncology Investor Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and...
Nov 18, 2021 08:00 am ET
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today released positive interim data on its lead...
Nov 12, 2021 07:30 am ET
Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that on November 11, 2021, it granted option...
Nov 09, 2021 07:00 am ET
Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration...
Nov 03, 2021 07:00 am ET
Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT™-GBM Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will host a key opinion leader...
Oct 27, 2021 02:00 pm ET
Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data at the American Society for Radiation...
Oct 21, 2021 04:05 pm ET
Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended...
Oct 19, 2021 07:30 am ET
Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced clearance of its Investigational New...
Oct 14, 2021 07:30 am ET
Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2021...
Sep 30, 2021 08:00 am ET
Plus Therapeutics to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present interim data on...
Sep 27, 2021 07:30 am ET
Plus Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and...
Sep 23, 2021 07:30 am ET
Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data regarding its...
Sep 13, 2021 07:00 am ET
Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company’s Chief Medical Officer
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the appointment of Norman LaFrance, M.D. to...
Sep 08, 2021 07:00 am ET
Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and...
Sep 02, 2021 08:30 am ET
Thinking about buying stock in Tiziana Life Sciences, Plus Therapeutics, ChargePoint, Support.com, or INmune Bio?
NEW YORK, Sept. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLSA, PSTV, CHPT, SPRT, and INMB.
Sep 02, 2021 07:00 am ET
Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has entered into an agreement...
Aug 21, 2021 09:23 am ET
Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data from the NIH-supported ReSPECTTM...
Aug 19, 2021 07:00 am ET
Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data from a preclinical study evaluating its...
Aug 13, 2021 07:51 am ET
Plus Therapeutics to Present Data from ReSPECT™-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on Rhenium-186 NanoLiposome...
Aug 11, 2021 10:12 am ET
Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will present data from one planned clinical trial...
Aug 05, 2021 07:30 am ET
Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and...
Jul 27, 2021 07:00 am ET
Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it entered into an exclusivity agreement with...
Jul 22, 2021 04:05 pm ET
Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the second quarter...
Jul 22, 2021 07:00 am ET
Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT™-GBM Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the first patient in the eighth cohort of the...
Jul 15, 2021 07:30 am ET
Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2021...
Jun 16, 2021 07:30 am ET
Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the Data and Safety Monitoring Board recommended the...
Jun 10, 2021 07:30 am ET
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology...
Jun 09, 2021 04:15 pm ET
Plus Therapeutics to Participate in BIO Digital Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO Digital Conference...
May 04, 2021 07:30 am ET
Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced two collaboration agreements to support its process...
Apr 22, 2021 04:05 pm ET
Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the first quarter ended March 31,...
Apr 08, 2021 07:30 am ET
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter 2021...
Mar 23, 2021 07:30 am ET
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has entered into a master services agreement (MSA)...
Mar 18, 2021 07:30 am ET
Plus Therapeutics to Participate in Upcoming Virtual Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive...
Mar 03, 2021 07:30 am ET
Plus Therapeutics to Participate in Upcoming Virtual Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive...
Feb 22, 2021 04:05 pm ET
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the fourth quarter and full year...
Feb 12, 2021 08:31 am ET
Thinking about buying stock in Can Fite Biopharma, Celsion Corp, Remark Holdings, Plus Therapeutics, or SenesTech?
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, CLSN, MARK, PSTV, and SNES.
Feb 11, 2021 04:15 pm ET
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year...
Feb 11, 2021 07:30 am ET
Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and...
Jan 05, 2021 04:15 pm ET
Plus Therapeutics to Participate in Upcoming January Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will...
Dec 15, 2020 07:30 am ET
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in...
Dec 08, 2020 07:30 am ET
Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been...
Dec 01, 2020 07:30 am ET
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson...
Nov 19, 2020 08:00 am ET
Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced positive new interim data from its...
Nov 16, 2020 08:00 am ET
Plus Therapeutics to Participate in Upcoming November Investor Conferences
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Company management has been invited to participate in two upcoming virtual investor...
Nov 13, 2020 07:30 am ET
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, personalized and targeted therapies for rare and difficult to treat cancers, today announced it will host a webinar on Thursday,...
Nov 12, 2020 07:25 am ET
Plus Therapeutics to Present at the virtual Fall Investor Summit on November 16th-18th
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Plus Therapeutics (NASDAQ:PSTV), is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets, including recurrent glioblastoma. PSTV will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.
Nov 05, 2020 07:00 am ET
Plus Therapeutics Announces Formation of Scientific Advisory Board
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced the formation of a Scientific Advisory Board (SAB) with the appointment of leading experts in...
Oct 29, 2020 07:00 am ET
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial...
Oct 22, 2020 04:05 pm ET
Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent business highlights. “Our lead investigational drug, RNL™ for recurrent...
Oct 15, 2020 07:00 am ET
Plus Therapeutics to Present at the Cancer Innovation Summit
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to participate in the Cancer Innovation Summit. The meeting, which is hosted by Health Tech Austin, is being held virtually on Thursday, October 22...
Oct 14, 2020 04:15 pm ET
Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that the company will report 2020 third quarter financial results on Thursday, October 22,...
Oct 02, 2020 07:00 am ET
Plus Therapeutics Announces Brain Cancer Clinical Advisory Team
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced the appointment of five leading experts in the fields of neurological surgery and neuro-oncology to its Clinical Advisory Board (CAB). The CAB will advise the Company as it...
Oct 01, 2020 07:00 am ET
ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes (RNL™), was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held...
Sep 15, 2020 07:00 am ET
Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for its lead investigational drug, Rhenium NanoLiposomes (RNL™), for the...
Sep 09, 2020 07:00 pm ET
Plus Therapeutics, Inc. to Present at the 22nd H. C. Wainwright Annual Global Investor Conference on September 15, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to present at the 22nd H. C. Wainwright Annual Global Investment Conference, which is being held virtually on September 14-16, 2020. Plus...
Sep 03, 2020 07:00 am ET
Plus Therapeutics, Inc. to Present at the 9th Annual Gateway Conference on September 10, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to present at the 9th Annual Gateway Conference, which is being held virtually on September 9-10, 2020. Plus Therapeutics, Inc. management is...
Sep 01, 2020 07:00 am ET
Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL™) for the...
Aug 31, 2020 05:00 pm ET
(LD Micro) 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 28, 2020 07:00 am ET
Plus Therapeutics, Inc. to Present at The LD 500 Virtual Conference
Plus Therapeutics, Inc (Exchange: PSTV) , today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 10.20 AM ET. Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation...
Aug 27, 2020 03:35 pm ET
9th Annual Gateway Conference to Virtually Showcase Leading Companies on September 9-10, 2020
Executives from a Range of Industries to Present to 500+ Institutional Investors & Analysts
Aug 10, 2020 07:43 am ET
Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020. Q2 2020 net loss was $1.8 million, or $0.45 per share, including...
Aug 03, 2020 07:00 am ET
Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Second Quarter Fiscal Year 2020 financial results after the close of market on August 10, 2020. The company plans to hold a conference call and live...
Jul 28, 2020 07:00 am ET
Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT™ Glioblastoma Clinical Trial and Expands Trial Sites
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas. The...
Jul 23, 2020 05:00 pm ET
Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day on Thursday, July 30 at 10:00 pm EST.  Dr. Marc Hedrick, President and CEO of Plus...
Jul 06, 2020 08:01 am ET
Plus Therapeutics Announces Inducement Stock Grants
Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that the compensation committee of the Company’s board of directors approved an inducement grant of stock options to purchase a total of 40,000 shares of common stock to Dr. Gregory Stein with...
May 14, 2020 04:27 pm ET
Plus Therapeutics Reports First Quarter 2020 Financial and Business Results
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial and business results for its first quarter fiscal year 2020 ended March 31, 2020. Fiscal 2020 first quarter net loss from continuing operations was $1.1 million,...
May 12, 2020 08:57 am ET
Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. Andrew Brenner, development leader of an innovative drug portfolio platform that the company has recently licensed, is scheduled to conduct a live patient-focused...
May 11, 2020 06:00 am ET
Plus Therapeutics Announces Closing of Agreement To License Novel Oncology Platform
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”, “Plus”), today announced the closing of its previously announced definitive agreement to license multiple rare cancer product candidates from private Texas-based radiotherapeutic company NanoTx...
May 07, 2020 04:15 pm ET
Plus Therapeutics To Report First Quarter Fiscal Year 2020 Financial Results and Corporate Update on May 14, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its First Quarter Fiscal Year 2020 financial results after the close of market on May 14, 2020. The company plans to hold a conference call and live audio...
Apr 16, 2020 04:15 pm ET
Plus Therapeutics to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020
AUSTIN, TX / ACCESSWIRE / April 16, 2020 / Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), today announced that it will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, April 22 at 4 PM EST. Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors.
Apr 06, 2020 07:00 am ET
Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it is donating personal protective equipment to San Diego’s Scripps Health for distribution to its front-line doctors, nurses and other health-care practitioners caring...
Apr 01, 2020 07:00 am ET
Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. Gregory Stein has joined the Company as Senior Vice President of Clinical Development. Dr. Stein is a highly regarded founder and executive of several healthcare and...
Mar 30, 2020 04:05 pm ET
Plus Therapeutics Reports Fourth Quarter and Full Fiscal Year 2019 Financial and Business Results
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”, “Plus”), today announced financial and business results for its Fourth Quarter and full Fiscal Year ended December 31, 2019. Fiscal 2019 Fourth Quarter net income from continuing...
Mar 30, 2020 07:15 am ET
Plus Therapeutics Licenses Novel Oncology Platform, Expands Pipeline
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has entered into a definitive agreement to license multiple rare cancer drug product candidates from private Texas-based radiotherapeutic company NanoTx Therapeutics,...
Mar 25, 2020 05:53 pm ET
Plus Therapeutics To Report Fourth Quarter and Full Fiscal Year 2019 Financial Results and Corporate Update on March 30, 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Fourth Quarter and full Fiscal Year 2019 financial results after the close of market on March 30, 2020.  The company plans to hold a conference call and...
Mar 12, 2020 07:15 am ET
Plus Therapeutics Welcomes Two New Directors
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. Robert Lenk and Mr. Howard Clowes will join the Company’s Board of Directors to serve as independent directors, effective April 1, 2020. Dr. Lenk has over 35 years as...
Feb 06, 2020 05:00 pm ET
Plus Therapeutics Announces Changes to its Board of Directors
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Greg B. Petersen has joined the Company’s Board of Directors to serve as an independent director, effective February 14, 2020.  Greg will serve on the Audit and...
Feb 06, 2020 05:00 pm ET
Plus Therapeutics Appoints Chief Financial Officer
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Andrew J. Sims has been appointed as the company’s Chief Financial Officer, effective February 5, 2020. A seasoned financial executive with two decades of leadership...
Jan 06, 2020 07:15 am ET
Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today issued the following Letter to Shareholders from Dr. Marc Hedrick, President and Chief Executive Officer. January 6, 2020 To Our Loyal Stockholders: All of us at Plus Therapeutics wish...
Jan 02, 2020 04:15 pm ET
Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. An van Es-Johansson has joined the Company’s Board of Directors to serve as an independent director, effective January 1, 2020. Dr. van Es-Johansson currently serves...
Dec 09, 2019 07:00 am ET
Plus Therapeutics to Present at Biotech Showcase 2020
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it has scheduled a company presentation at Biotech Showcase 2020, to be held January 13-15, 2020 during the most important week in healthcare.  Dr. Marc Hedrick,...
Nov 25, 2019 07:00 am ET
Plus Therapeutics to Present at the LD Micro Main Event (XII)
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will be participating at the upcoming 12th annual LD Micro Main Event.  Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics, will be presenting...
Nov 14, 2019 04:05 pm ET
Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced financial and business results for the third quarter of 2019. Third quarter 2019 net income from continuing operations was $0.5 million, or $0.03 per share. Total net...
Nov 04, 2019 07:00 am ET
Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Fiscal 2019 Third Quarter financial results after the close of market on November 14, 2019. The company plans to hold a conference call and live audio...
Oct 15, 2019 09:20 am ET
Plus Therapeutics Receives $4.6MM Reimbursement Payment
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it received a $4.6 million payment from the U.S. Department of Health and Human Services / Office of the Assistant Secretary for Preparedness and Response / Biomedical...
Sep 26, 2019 04:10 pm ET
Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 3,000,000 units, each unit consisting of one share of common stock (or a common stock...
Sep 23, 2019 12:15 pm ET
Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 3,000,000 units, each unit consisting of one share of common stock (or a common stock equivalent) and one...
Sep 23, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Exact Sciences, Plus Therapeutics, or Arcadia Biosciences?
NEW YORK, Sept. 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, EXAS, PSTV, and RKDA.
Sep 23, 2019 06:10 am ET
Plus Therapeutics to Receive $4.6MM Reimbursement Payment
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it received notice from the U.S. Department of Health and Human Services / Office of the Assistant Secretary for Preparedness and Response / Biomedical Advanced Research...
Aug 15, 2019 07:21 pm ET
Plus Therapeutics Reports Q2 2019 Financial and Business Results
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced Q2 2019 financial results and provided updates on corporate activities. Q2 2019 net loss from continuing operations was $2.3 million, or $5.12 per share. Q2 2019 total net loss...
Jul 29, 2019 07:30 am ET
Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that the Company has officially changed its name from “Cytori Therapeutics, Inc.” to “Plus Therapeutics, Inc.” and the ticker symbol for the Company’s common stock on the Nasdaq...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.